Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. The request metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd.; this discrepancy should be verified.
Reporting period: December 2023, Report No. 3. Filed December 4, 2023, under Form 6-K for a foreign private issuer.
Business Context and Corporate Actions
On November 28, 2023, NLS Pharmaceutics announced that Claudio L. A. Bassetti and Florence Allouche Aknin were appointed to its board of directors, effective January 1, 2024.
Financial Position and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, cash balance, liquidity, or other operating financial metrics.
On November 10, 2023, PricewaterhouseCoopers AG requested balance sheets prepared on both going-concern and liquidation-value bases as of October 31, 2023, under Articles 725 and 725b(1) of the Swiss Code of Obligations. The request was intended to assess whether liabilities exceeded assets.
On December 4, 2023, the auditor stated that, after reviewing the requested financial information, it concluded that, for the time being, the board had taken the required actions described in the auditor’s original letter.
Material Changes, Outlook, and Risks
- Two new board members will join effective January 1, 2024.
- The auditor’s communications indicate a potential Swiss statutory capital or balance-sheet concern, although the filing does not disclose the underlying balance-sheet amounts or the specific corrective actions taken.
- No financial guidance, operating outlook, forecast, contingency amount, or going-concern conclusion is provided.
- The report is incorporated by reference into the company’s specified Form F-3 registration statements, subject to later filings.
Key Facts for Investors to Verify
- Confirm the registrant’s identity, given the discrepancy between the request metadata and the filing.
- Review the October 31, 2023 balance sheets and any subsequent financial statements for evidence of excess liabilities over assets.
- Determine the actions taken by the board in response to the auditor’s November 10 letter.
- Assess the backgrounds and expected roles of the two incoming directors.
- Review Exhibit 99.1 and subsequent filings for additional governance, financing, or liquidity information.